Telitacicept用于耐火ACHR阳性泛性肌痛性肌痛症:一个回顾性的真实世界研究
Xi Rong1, Xupeng Sun1, Li Wang1
1Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Frontiers in immunology
|February 25, 2026
概括
泰利塔西在治疗耐火性乙胆受体阳性通用化骨髓灰质炎 (AChR+gMG) 中显示出显著的疗效,可能减少长期免疫抑制剂的需要,并提供一种新的治疗选择.
科学领域:
- 免疫学 免疫学 免疫学
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 耐火性乙胆受体阳性通用化骨髓灰质炎 (AChR+gMG) 提出了治疗挑战.
- 现有的疗法往往缺乏特异性,并带有长期风险.
- 作为B淋巴细胞刺激剂 (BLyS) 和增殖诱导配体 (APRIL) 的双重抑制剂,特利塔西塞普提供了一种有针对性的方法.
研究的目的:
- 为了评估telitacicept在耐火性ACHR+gMG患者中的疗效和安全性.
- 评估特利塔西塞普对定量肌痛严重症 (QMG) 评分的影响.
- 为了确定降低同时使用免疫抑制药物的潜力.
主要方法:
- 一项回顾性研究涉及42名耐火性ACHR+gMG.G患者.
- 使用混合效应模型从基线对QMG得分的变化进行分析.
- 评估累积反应率,药物减少和安全事件.
主要成果:
- 观察到QMG总分数的显著改善 (LS在5个月的平均变化: -2.24,p<0.001).
- 在眼睛,四肢和腹筋症状中注意到持续的好处.
- 6个月后高累积反应率 (69.9%的MGFA-PIS,73.8%的QMG改善).
- 显著减少了普得尼松和其他免疫抑制剂的使用.
- 泰利塔西塞普特表现出了有利的安全性.
结论:
- 泰利塔西塞普在治疗耐火性ACHR+gMG时是有效的.
- 该药物可能会减少对传统免疫抑制剂的依赖.
- 现实世界的数据支持telitacicept作为这个患者群体的有价值的治疗选择.
相关概念视频
Myasthenia Gravis: Overview and Treatment
3.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.1K
Myasthenia Gravis: Diagnostic Tests
2.8K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
2.8K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
646
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
646
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
568
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
568
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)

